Evidence map›Paper›PMID 41199672›Full record

ArticleChemistry (Weinheim an der Bergstrasse, Germany)2025

Development of Synthetic Routes to 2'-O,4'-C-Spirocyclopentylene-Bridged Nucleic Acids: Thymidine, Guanosine, and Adenosine.

Riku Kumagai, Riko Yamada, Takao Yamaguchi, Satoshi Obika

Abstract read
In one paragraph

Article in Chemistry (Weinheim an der Bergstrasse, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Riku KumagaiSchool of Pharmaceutical Sciences, The University of Osaka, 1-6 Yamadaoka, Suita, Osaka, 565-0871, Japan.
Riko YamadaSchool of Pharmaceutical Sciences, The University of Osaka, 1-6 Yamadaoka, Suita, Osaka, 565-0871, Japan.
Takao YamaguchiGraduate School of Pharmaceutical Sciences, The University of Osaka, 1-6 Yamadaoka, Suita, Osaka, 565-0871, Japan.ORCID https://orcid.org/0000-0003-3180-0257
Satoshi ObikaGraduate School of Pharmaceutical Sciences, The University of Osaka, 1-6 Yamadaoka, Suita, Osaka, 565-0871, Japan.ORCID https://orcid.org/0000-0002-6842-6812

Funding

Hoansha FoundationJapan Agency for Medical Research and Development JP19am0101084Japan Agency for Medical Research and Development JP19am0401003Japan Agency for Medical Research and Development JP21ae0121022Japan Agency for Medical Research and Development JP21ae0121023Japan Agency for Medical Research and Development JP21ae0121024Japan Agency for Medical Research and Development JP22ama121054Japan Society for the Promotion of Science 20K05748Open and Transdisciplinary Research Initiatives
6 · The paper itself

Abstract

Modified nucleic acids are crucial for improving the efficacy and safety of antisense oligonucleotides (ASOs). We previously synthesized and evaluated 2'-O,4'-C-spirocyclopentylene-bridged nucleic acid (scpBNA2) bearing the pyrimidine nucleobases thymine (T) and 5-methylcytosine (

Indexed as

AdenosineGuanosineNucleic AcidsOligonucleotides, AntisenseThymidineHumansOligonucleotidesThymineAdenosineGuanosineNucleic AcidsOligonucleotidesOligonucleotides, AntisenseThymidineThymineiodocyclizationmodified nucleic acidnucleoside synthesisoligonucleotide therapeuticstransglycosylation

Identifiers

PMID41199672
PMCPMC12712746

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.